SPARC and gastric cancer: Further analysis of preoperative chemotherapy in group A revealed that 15 (27.8%) of 54 GC patients in group A underwent taxanes-based chemotherapy, among which 60.0% showed low SPARC expression in post-chemotherapy specimens.